ALKERMES Inspiration Grants™ Awarded to Support People Affected by Mental Health and Substance Use Disorders
November 03 2016 - 7:00AM
Business Wire
–– $1 Million Awarded for the Development or
Expansion of Innovative Programs Serving Mental Health and
Addiction Communities ––
Alkermes plc (NASDAQ: ALKS), a global biopharmaceutical company
developing medicines for the treatment of central nervous system
(CNS) diseases, today announced the company has awarded $1 million
in funds to non-profit patient and community organizations as part
of its newly launched ALKERMES Inspiration Grants™ program. The
competitive grant program was designed to fund innovative and
high-impact programs to support people affected by mental health
and substance use disorders.
“We have learned that our efforts to develop innovative new
medicines to treat those affected by mental health and substance
use disorders only address part of the needs of patients and their
families,” said Richard Pops, Chief Executive Officer of Alkermes.
“To most effectively address the myriad of other needs of those
suffering from addiction and mental illness, a whole societal
infrastructure must be in place and operational. We often take this
for granted, but services for these disease areas are desperately
needed. This program seeks to support ideas within the community to
catalyze change.”
More than 300 proposals were received from local, regional and
national non-profit organizations across the United States. Ten
Innovation Grants (up to $100,000) and five Emergence Grants (up to
$25,000) were awarded to programs demonstrating the potential for
high-impact, an ability to be replicated across the ecosystem
and/or inventive, and creative approaches to support the broader
needs of people in the mental health and addiction communities. To
view the full list of recipients and reviewers, please click
here.
“We found both the response to the program and the high quality
of the submissions to be inspiring,” commented Nikki Levy, Vice
President of Patient Engagement at Alkermes. “We are excited to see
the impact that the selected programs will make across the country
and look forward to continuing the program next year. While we are
only able to fund a limited number of the requests, we are
confident that all of this year’s applicants will continue to drive
change and support people affected by serious mental illness and
substance use disorders.”
Awards went to large advocacy organizations, academic
institutions and regional organizations. The selected programs
include initiatives focused on peer support; connecting individuals
to appropriate care, wellness and skill development in the criminal
justice system; youth education and support services, as well as
programs designed to help others understand the experience of
individuals living with mental health conditions and substance use
disorders.
“The National Sheriffs’ Association (NSA) is honored, delighted
and grateful to receive this prestigious award,” said Timothy O.
Woods, J.D., M.A., LL.M., Director of Grants & Contracts at the
National Sheriffs’ Association. “We thank Alkermes for this award
to NSA and, moreover, for Alkermes’ commitment to supporting the
initiatives and good work of organizations nationwide through its
creation of the ALKERMES Inspiration Grants program.”
Selected programs were chosen by Alkermes in partnership with a
group of external reviewers who represent the perspectives of the
community. These reviewers included a patient advocate, a
representative from the criminal justice system, a person in
recovery and a caregiver. Proposals were evaluated based on a
standard set of review criteria, which included potential impact,
identification of need and creativity of the solution, the
organization’s ability to execute, and the sustainability of the
program.
For more information on ALKERMES Inspiration Grants program,
please visit www.alkermes.com/inspirationgrants.
About Alkermes
Alkermes plc is a fully integrated, global
biopharmaceutical company developing innovative medicines for the
treatment of central nervous system (CNS) diseases. The company has
a diversified commercial product portfolio and a substantial
clinical pipeline of product candidates for chronic diseases that
include schizophrenia, depression, addiction and multiple
sclerosis. Headquartered in Dublin, Ireland, Alkermes plc has an
R&D center in Waltham, Massachusetts; a research and
manufacturing facility in Athlone, Ireland; and a manufacturing
facility in Wilmington, Ohio. For more information, please visit
Alkermes’ website at www.alkermes.com.
ALKERMES Inspiration Grants™ is a trademark of Alkermes,
Inc.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20161103005293/en/
Alkermes Contacts:For Investors:
Sandy Coombs, +1 781 609 6377orEva Stroynowski, +1 781 609
6823orFor Media:Jennifer Snyder, +1 781 609 6166
Alkermes (NASDAQ:ALKS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Alkermes (NASDAQ:ALKS)
Historical Stock Chart
From Apr 2023 to Apr 2024